Gyeonggi-do, South Korea

Dong-Jin Lee

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 2.4

ph-index = 3

Forward Citations = 45(Granted Patents)


Location History:

  • Kwangmyeong, KR (1996)
  • Kwanmyeong, KR (1997)
  • Suwon-shi, KR (2008)
  • Gyeonggi-do, KR (2005 - 2019)

Company Filing History:


Years Active: 1996-2019

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovations of Dong-Jin Lee

Introduction

Dong-Jin Lee is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, holding a total of seven patents. His work focuses on improving the stability and formulation of pharmaceutical compositions.

Latest Patents

One of Dong-Jin Lee's latest patents is a pharmaceutical composition containing clomipramine and a preparation method for it. This invention provides a pharmaceutical formulation that includes clomipramine or its pharmaceutically acceptable salt, specifically clomipramine hydrochloride, as the first active ingredient. The second active ingredient is sildenafil or its pharmaceutically acceptable salt, preferably sildenafil citrate. The formulation aims to improve the stability of clomipramine and outlines a method for manufacturing this pharmaceutical formulation using a wet granulation method.

Career Highlights

Throughout his career, Dong-Jin Lee has worked with prominent companies such as Samsung Electronics Co., Ltd. and Ctc Bio, Inc. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.

Collaborations

Dong-Jin Lee has collaborated with notable individuals in his field, including Moon-noh Lee and Hyun-seok Yang. These collaborations have likely enhanced his research and development efforts.

Conclusion

Dong-Jin Lee's contributions to pharmaceutical formulations demonstrate his commitment to innovation and improvement in the industry. His patents reflect a deep understanding of the complexities involved in drug formulation and stability.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…